Subtype
Pancreatobiliary Carcinoma
CI-CAN-00001365Explore in graph →
700 active trials8 approved drugs60 evidence items
- NCIt
- C166418
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001365Explore in graph →
Clinical trials
2,132 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (303)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06906562 | A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations | recruiting | Phase 2 | 40 | Sameek RoychowdhuryOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07145255 | Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | MBrace TherapeuticsINDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06384560 | Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)(PREOPANC-5) | recruiting | Phase 1 / Phase 2 | 66 | Amsterdam UMC, location VUmcOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06778863 | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation(GUARDIAN-101) | recruiting | Phase 1 | 90 | Clasp Therapeutics, Inc.INDUSTRY | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07240766 | HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation | recruiting | Phase 2 | 40 | Zhejiang UniversityOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT02775461 | Pancreas Registry and High Risk Registry | recruiting | — | 1,368 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT05430698 | PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma | recruiting | Phase 2 | 62 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07223307 | REGULUS: MRI-guided Adaptive SABR for Liver Cancers | recruiting | Phase 2 | 62 | Stanford UniversityOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT03740256 | Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors(VISTA) | recruiting | Phase 1 | 45 | Baylor College of MedicineOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07201519 | Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy | recruiting | Phase 2 | 80 | Michael J Cavnar, MDOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06313203 | HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)(TOMCAT) | recruiting | Phase 2 | 39 | Oslo University HospitalOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06861088 | The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer(CATIQ P3) | recruiting | Phase 3 | 480 | Quercis Pharma AGINDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07030283 | Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis | recruiting | Phase 1 | 10 | University of Colorado, DenverOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04150042 | SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells(SHARON) | recruiting | Phase 1 | 24 | General Oncology, Inc.INDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07364305 | HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC(Lalo) | recruiting | Phase 2 | 50 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07359586 | Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia | recruiting | — | 1,200 | Zhejiang UniversityOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07328607 | Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy | recruiting | N/A | 90 | Minia UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07342231 | FAPi PET in Pancreatic Ductal Adenocarcinoma(FAP-1) | recruiting | — | 60 | Tata Memorial HospitalOTHER_GOV | 1 | Jan 15, 2026 | clinicaltrials |
| NCT05668884 | GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma | recruiting | Phase 2 | 93 | Fudan UniversityOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT03977233 | Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer | recruiting | Phase 2 | 45 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07235007 | Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic Cholangiocarcinoma(BRAVE) | recruiting | N/A | 120 | Aichi Medical UniversityOTHER | 2 | Jan 13, 2026 | clinicaltrials |
| NCT07337850 | Prospective Evaluation of 68Ga-FAPI PET in Biliary Cancers(FAPi-2) | recruiting | — | 60 | Tata Memorial CentreOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05679674 | Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer | recruiting | N/A | 48 | Baptist Health South FloridaOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06073431 | LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia(LOTUS) | recruiting | — | 800 | University of RochesterOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06693986 | Adenovirus (RGDCRAdCOX2F) | recruiting | Phase 1 | 18 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06999187 | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | recruiting | Phase 1 | 96 | Dren BioINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04353375 | HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 / Phase 3 | 235 | HutchmedINDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06715839 | Target-specific immunoPET Imaging of Digestive System Carcinoma | recruiting | N/A | 400 | RenJi HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT04146298 | Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 30 | Changhai HospitalOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07262957 | Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)(PANENCA) | recruiting | Phase 4 | 400 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07291063 | Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA | recruiting | — | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07291947 | PULSAR Combined With Immunotherapy and Chemotherapy | recruiting | Phase 1 / Phase 2 | 60 | Wang XinOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06730009 | Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients | recruiting | Phase 1 / Phase 2 | 42 | Medigen Biotechnology CorporationINDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06416397 | Diagnostic Approach for Cholangiocarcinoma Using Liquid Bile Biopsy(PROTEOBILE) | recruiting | — | 200 | University Hospital, BordeauxOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07284277 | TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC) | recruiting | Phase 1 / Phase 2 | 30 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT06546969 | Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer | recruiting | Phase 1 | 15 | University of Maryland, BaltimoreOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT07269626 | PULSAR in Systemic Therapy for Pancreatic Cancer | recruiting | Phase 2 | 47 | Samsung Medical CenterOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT04570943 | Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer(GABRINOX-ART) | recruiting | Phase 2 | 103 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT07263217 | Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver Injury | recruiting | N/A | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06333314 | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI(Pan-MSI-ACSE) | recruiting | Phase 2 | 120 | UNICANCEROTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07230509 | Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate(NBCA) | recruiting | Phase 2 | 90 | Minia UniversityOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07232810 | Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer(TMpE) | recruiting | N/A | 90 | Minia UniversityOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07259590 | A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation | recruiting | Phase 1 / Phase 2 | 126 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06440993 | Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 42 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07241663 | Surgery for Locally Unresectable Pancreatic Cancer(ROBIN) | recruiting | — | 150 | Azienda Ospedaliera di PadovaOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07106827 | A Study of GV20-0251 in Advanced or Refractory Solid Tumors | recruiting | Phase 1 | 10 | West China HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07237464 | To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GB18 Injection in Healthy Participants | recruiting | Phase 1 | 36 | Shenzhen Kexing Pharmaceutical Co., Ltd.NETWORK | 1 | Nov 19, 2025 | clinicaltrials |
| NCT04115254 | Stereotactic Magnetic Resonance Guided Radiation Therapy | recruiting | N/A | 397 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 13, 2025 | clinicaltrials |
| NCT06600906 | Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer | recruiting | — | 70 | University of California, San FranciscoOTHER | 1 | Nov 12, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 17, 2026source: clinicaltrials